Effectiveness of tolvaptan on renal replacement therapy in patients with autosomal dominant polycystic kidney disease: a retrospective cohort study from the TriNetX global collaborative network. [PDF]
Ren FailWu MJ, Chen CH, Tsai SF.
europepmc +1 more source
Case report: Persistent syndrome of inappropriate antidiuresis after traumatic brain injury: spontaneous resolution and impact on RAAS and bone metabolism over five years. [PDF]
Front Endocrinol (Lausanne)Liu Y +5 more
europepmc +1 more source
Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases. [PDF]
Sci RepUno T, Hosomi K, Yokoyama S.
europepmc +1 more source
Low-dose tolvaptan to control disease progression in Chinese patients with autosomal dominant polycystic kidney disease: a retrospective cohort study. [PDF]
Transl Androl UrolZhou L, Wei X, Wang B, Xu Q, Li W.
europepmc +1 more source
Association of Early Tolvaptan Treatment and Length of In Hospital Stay in Elderly Patients with Acute Decompensated Heart Failure. [PDF]
JMA JSuzuki S +10 more
europepmc +1 more source
A Rare Coexisting Presentation of Autosomal Dominant Polycystic Kidney Disease With Rapid Deterioration of Renal Function and Neurofibromatosis Type 1. [PDF]
CureusNoishiki H +4 more
europepmc +1 more source
What is the Appropriate Dose of Tolvaptan in ADPKD?
Kidney International ReportsDahl, Neera K., Torres, Vicente E.
openaire +2 more sources
The Effect of Tolvaptan on Metabolism and Electrolyte Homeostasis in Patients with Heart Failure: A Systematic Review and Meta-Analysis. [PDF]
Rev Cardiovasc MedXiao Y +5 more
europepmc +1 more source
Tolvaptan and the role of kidney aquaporin-2 abundance in managing volume overload in patients with CKD. [PDF]
Clin Kidney JYan Y +8 more
europepmc +1 more source